Optimizing Gastroenterology Prior Authorization in Massachusetts

The Massachusetts Context for GI Prior Authorization

Massachusetts' healthcare environment, characterized by a mix of state-specific Medicaid managed care plans and a robust commercial payer footprint, significantly influences prior authorization workflows for gastroenterology. Practices must contend with varying payer policies for high-cost biologics, advanced imaging, and endoscopic procedures, making a standardized approach challenging. This diversity necessitates agile systems that can adapt to multiple payer requirements efficiently.

High-Volume PA Categories in Massachusetts Gastroenterology

• **IBD Biologics:** TNF inhibitors (adalimumab, infliximab), integrin inhibitors (vedolizumab), IL-12/23 inhibitors (ustekinumab), JAK inhibitors (tofacitinib, upadacitinib), S1P modulators (ozanimod, etrasimod), and risankizumab for Crohn's disease, often requiring periodic re-authorization.
• **Hepatitis C Direct-Acting Antivirals:** Medications like sofosbuvir-velpatasvir and glecaprevir-pibrentasvir, with PA pathways differing for treatment-naive vs. treatment-experienced patients.
• **Advanced Imaging:** MRCP, MR enterography, and CT enterography for IBD assessment and other abdominal conditions.
• **Endoscopic Procedures:** Specific PA requirements for capsule endoscopy (CPT 91110), small-bowel enteroscopy, ERCP, and EUS for diagnostic and therapeutic indications.
• **Specialty Drugs for Functional GI Disorders:** Including eluxadoline for IBS-D and prucalopride for chronic constipation, which often have specific step therapy requirements.

Common Documentation Hurdles and Denial Triggers

Gastroenterology prior authorizations in Massachusetts often face denials due to specific documentation gaps. For IBD biologics, common issues include insufficient disease severity assessment (e.g., missing Mayo score), lack of documented conventional therapy trials, or non-compliance with biosimilar substitution policies. Hepatitis C DAA denials frequently stem from missing genotype or fibrosis stage documentation. Klivira's platform is designed to identify and flag these requirements proactively, aligning with ACG, AGA, and AASLD guidelines.

Addressing Chronic Treatment and Benefit Splits

The nature of chronic GI conditions, particularly IBD, means ongoing prior authorization burden for biologics, with re-authorizations typically required every 6-12 months. Furthermore, the split between medical and pharmacy benefits for provider-administered infusions versus self-administered injections of the same biologic agent adds a layer of complexity. Klivira's system streamlines periodic re-authorization workflows and intelligently routes requests based on the administration mode, ensuring continuity of care for Massachusetts patients.

Klivira's Solution for Massachusetts GI Practices

Klivira integrates with leading EMRs via SMART on FHIR, automating the submission and tracking of gastroenterology prior authorization requests. Our platform incorporates payer-specific logic for Massachusetts' diverse commercial and Medicaid managed care plans, addressing complex step therapy requirements for IBD biologics and precise documentation needs for Hepatitis C DAAs. By leveraging X12 278 and ePA standards, Klivira reduces manual effort and accelerates approval times, improving revenue capture for GI practices across the state.